A
Arnon Nagler
Researcher at Sheba Medical Center
Publications - 1435
Citations - 51740
Arnon Nagler is an academic researcher from Sheba Medical Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 98, co-authored 1316 publications receiving 44298 citations. Previous affiliations of Arnon Nagler include French Institute of Health and Medical Research & University of Paris.
Papers
More filters
Journal ArticleDOI
Reduced-intensity conditioning for allogeneic stem cell transplantation: 10 years later.
Journal ArticleDOI
Longitudinal outcome over two decades of unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: an ALWP/EBMT analysis.
Arnon Nagler,M. Ngoya,Jacques-Emmanuel Galimard,Myriam Labopin,Martin Bornhäuser,Matthias Stelljes,Jürgen Finke,Arnold Ganser,Hermann Einsele,Nicolaus Kröger,Arne Brecht,Wolfgang Bethge,Matthias Edinger,A. D. Kulagin,Jakob Passweg,Igor Wolfgang Blau,Ahmet H. Elmaagacli,Kerstin Schäfer-Eckart,Uwe Platzbecker,Thomas Schroeder,Donald Bunjes,Johanna Tischer,Sonja Martin,Alexandros Spyridonidis,Sebastian Giebel,B. Savani,Mohamad Mohty +26 more
TL;DR: Outcome of unrelated transplantation for patients with ref/rel AML has improved in the last two decades, rescuing about one third of the patients.
Journal ArticleDOI
Development and validation of a simplified score to predict early relapse in newly diagnosed multiple myeloma in a pooled dataset of 2,190 patients
Gian Maria Zaccaria,Luca Bertamini,Maria Teresa Petrucci,Massimo Offidani,Paolo Corradini,Andrea Capra,Alessandra Romano,Anna Marina Liberati,Donato Mannina,Paolo de Fabritiis,Nicola Cascavilla,Marina Ruggeri,Roberto Mina,Francesca Patriarca,Giulia Benevolo,Angelo Belotti,Gianluca Gaidano,Arnon Nagler,Roman Hájek,Andrew Spencer,Pieter Sonneveld,Pellegrino Musto,Mario Boccadoro +22 more
TL;DR: In this paper, a simplified early relapse in multiple myeloma (S-ERMM) score was proposed to identify three patient groups with different risks of ER18: Intermediate (Int) versus Low (OR = 2.39, P
Journal ArticleDOI
Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party.
Andrea Necchi,Rosalba Miceli,M. Bregni,Carsten Bokemeyer,Lars Arne Berger,Karin Oechsle,K. Schumacher,Edward Kanfer,J. H. Bourhis,Christophe Massard,Daniele Laszlo,Juan Montoro,Aude Flechon,Fikret Arpaci,S. Secondino,Patrick Wuchter,Peter Dreger,Martina Crysandt,Nina Worel,William Krüger,Mark Ringhoffer,Ali Ünal,Arnon Nagler,A Campos,Anders Wahlin,Mariagrazia Michieli,Gülsan Türköz Sucak,I. Donnini,Rik Schots,Norbert Ifrah,Manuela Badoglio,Massimo Martino,Daniele Raggi,Patrizia Giannatempo,Giovanni Rosti,Paolo Pedrazzoli,Francesco Lanza +36 more
TL;DR: In this paper, the prognostic impact of prior paclitaxel therapy and response to induction chemotherapy defined as the regimen preceding high-dose chemotherapy (HDCT) for the salvage therapy of advanced germ cell tumors was investigated.
Journal ArticleDOI
The modulation of plasma lipids and lipoproteins during bone marrow transplantation is unrelated to exogenously administered recombinant human granulocyte-monocyte colony-stimulating factor (rHu GM-CSF)
TL;DR: It is concluded that BMT has a significant transient effect on plasma lipids and lipoproteins and although this response is unrelated to the exogenous administration of rHu GM-CSF it may be causally related to endogenous cytokines or other, yet unidentified, factors.